A Phase 3 interventional study of Fingolimod and Placebo in Relapsing Remitting Multiple Sclerosis (RRMS), sponsored by Novartis Pharmaceuticals. Terminated at 44 sites in 11 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-08-08.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.
Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one is the 10th largest by enrollment, is one of 6 that started in 2011, is one of 5 in phase 3, and was the 7th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 6 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 142 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 142 across the 19 interventional studies. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 19 have an industry lead sponsor. The 5 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis: 1 open now, 4 under way, none of them phase 3. Of 28 finished, 19 (68%) have results posted.
Among the 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis, this one is the 14th largest by enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2011, is one of 5 in phase 3, and was the 10th registered.
Novartis’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Among Novartis’s 34 in Multiple Sclerosis, Relapsing-Remitting:
This tab as a report to print or save as PDF → With an account.
This study evaluated disease control during different lengths of treatment transition from natalizumab to fingolimod.
Patient were screened, signed an informed consent at visit 1, at the 2nd visit, all patient received a baseline infusion of Natalizumub and subsequently randomized to one of 3 treatment arms. At the randomization visit, the Washout Phase started, and eligible patients were randomized 1:1:1 to one of three treatment groups:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must:
Exclusion Criteria:
Patients with:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
8-week washout (8 weeks no treatment) followed by 24 weeks of treatment with fingolimod 0.5mg once a day
Drug: Fingolimod
12-week washout (8 weeks no treatment and 4 weeks placebo) followed by 20 weeks of treatment with fingolimod 0.5mg once a day
Drug: Fingolimod · Drug: Placebo
16-week washout (8 weeks no treatment and 8 weeks placebo) followed by 16 weeks of treatment with fingolimod 0.5mg once a day
Drug: Fingolimod · Drug: Placebo
Fingolimod 0.5 mg capsules for oral administration once daily
Matching placebo in capsules for oral administration once daily.
Number of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) Through 8 Weeks of Fingolimod Treatment
Active lesions were measured on brain MRI scans, performed at week 8, compared to the prior scan. The primary variable was analyzed by fitting a negative binomial regression model adjusted for washout group.
Time frame: Number of active T2 lesions from last natalizumab dose through 8 weeks of fingolimod treatment
Number of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) up to the Initiation of Fingolimod Treatment
Lesions were measured by MRIs and the number of active (new or newly enlarging) T2 lesions was calculated from baseline to beginning of treatment.
Time frame: 8, 12 and 16 weeks (number of active T2 lesions during the washout period only)
Number of Active (New or Newly Enlarging) T2 Lesions During the First 8 Weeks of Fingolimod Treatment
Lesions were measured by MRIs and the number of active (new or newly enlarging) T2 lesions was calculated for first 8 weeks of fingolimod treatment.
Time frame: Number of active T2 lesions during 8 wks of fingolimod treatment
Number of Active (New or Newly Enlarging) T2 Lesions During the 24 Weeks After the Last Natalizumab Infusion (Baseline)
Lesions will be measured by MRIs and the number of active (new or newly enlarging) T2 lesions will be calculated for 24 weeks from baseline.
Time frame: Baseline up to 24 weeks
Change From Baseline in Expanded Disability Status Scale (EDSS) by Washout Group
Kurtzke's Expanded Disability Status Scale (EDSS) measures the changes in neurologic impairment, either chronic (progression over time), or acute (MS relapses). The EDSS steps range from 0 (normal) to 10 (death due to MS). Relapse severity is assessed based on severity of neurologic impairment as evaluated using the EDSS.
Time frame: Baseline to week 16 and week 32
Cumulative Number of Gadolinium-enhancing T1 Lesions From the Last Natalizumab Infusion
Gadolinium-enhancing lesions will be measured on post-contrast T1-weighted brain MRI scans
Time frame: 8 weeks and 24 weeks
Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and Death During Washout Period
Adverse events were summarized by the number of patients having any adverse event overall.
Time frame: Baseline to maximum of 16 weeks
Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and Death During Fingolimod Treatment
Adverse events were summarized by the number of patients having any adverse event overall.
Time frame: Baseline to maximum of 16 weeks
Of the 158 patients screened, 142 patients were randomized.
| Milestone | 8-week Washout + Fingolimod (FTY720) | 12-week Washout + Fingolimod (FTY720) | 16-week Washout + Fingolimod (FTY720) |
|---|---|---|---|
| Started | 50 | 42 | 50 |
| Full analysis set (fas) | 49 | 42 | 50 |
| Modified full analysis set | 41 | 29 | 39 |
| Completed | 41 | 31 | 40 |
| Not completed | 9 | 11 | 10 |
| Withdrew: Administrative problems | 4 | 5 | 5 |
| Withdrew: Protocol violation | 1 | 3 | 2 |
| Withdrew: Adverse event | 0 | 2 | 2 |
| Withdrew: Withdrawal by subject | 2 | 1 | 1 |
| Withdrew: Lack of efficacy | 2 | 0 | 0 |
Active lesions were measured on brain MRI scans, performed at week 8, compared to the prior scan. The primary variable was analyzed by fitting a negative binomial regression model adjusted for washout group.
| Count of Active T2 Lesions | 8-week Washout + Fingolimod (FTY720) | 12-week Washout + Fingolimod (FTY720) | 16-week Washout + Fingolimod (FTY720) |
|---|---|---|---|
| Number of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) Through 8 Weeks of Fingolimod Treatment | 2.1 ± 7.24 | 1.7 ± 3.78 | 8.2 ± 16.81 |
Lesions were measured by MRIs and the number of active (new or newly enlarging) T2 lesions was calculated from baseline to beginning of treatment.
| Count of active T2 lesions | 8-week Washout + Fingolimod (FTY720) | 12-week Washout + Fingolimod (FTY720) | 16-week Washout + Fingolimod (FTY720) |
|---|---|---|---|
| Number of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) up to the Initiation of Fingolimod Treatment | 0.4 ± 2.71 | 2.1 ± 11.15 | 3.6 ± 7.54 |
Lesions were measured by MRIs and the number of active (new or newly enlarging) T2 lesions was calculated for first 8 weeks of fingolimod treatment.
| Count of Active T2 Lesions | 8-week Washout + Fingolimod (FTY720) | 12-week Washout + Fingolimod (FTY720) | 16-week Washout + Fingolimod (FTY720) |
|---|---|---|---|
| Number of Active (New or Newly Enlarging) T2 Lesions During the First 8 Weeks of Fingolimod Treatment | 1.5 ± 4.56 | 2.1 ± 5.50 | 4.2 ± 10.24 |
Lesions will be measured by MRIs and the number of active (new or newly enlarging) T2 lesions will be calculated for 24 weeks from baseline.
| Count of Active T2 Lesions | 8-week Washout + Fingolimod (FTY720) | 12-week Washout + Fingolimod (FTY720) | 16-week Washout + Fingolimod (FTY720) |
|---|---|---|---|
| Number of Active (New or Newly Enlarging) T2 Lesions During the 24 Weeks After the Last Natalizumab Infusion (Baseline) | 3.2 ± 10.07 | 4.4 ± 16.01 | 7.7 ± 16.28 |
Kurtzke's Expanded Disability Status Scale (EDSS) measures the changes in neurologic impairment, either chronic (progression over time), or acute (MS relapses). The EDSS steps range from 0 (normal) to 10 (death due to MS). Relapse severity is assessed based on severity of neurologic impairment as evaluated using the EDSS.
| Units on a scale | 8-week Washout + Fingolimod (FTY720) | 12-week Washout + Fingolimod (FTY720) | 16-week Washout + Fingolimod (FTY720) |
|---|---|---|---|
| Week 16 (n=40, 33, 39) | 0.11 ± 0.330 | -0.03 ± 0.529 | 0.23 ± 0.706 |
| Week 32 (n= 40,30,39) | 0.11 ± 0.625 | -0.13 ± 0.524 | 0.08 ± 0.748 |
Gadolinium-enhancing lesions will be measured on post-contrast T1-weighted brain MRI scans
| Number of Gd enhanced T1 Lesions | 8-week Washout + Fingolimod (FTY720) | 12-week Washout + Fingolimod (FTY720) | 16-week Washout + Fingolimod (FTY720) |
|---|---|---|---|
| Week 8 (n=1,1,0) | 25.0 ± 0 | 2.0 ± 0 | NA ± NA |
| Week 24 (n=10,12,21) | 6.3 ± 9.45 | 3.4 ± 4.54 | 3.6 ± 4.49 |
Adverse events were summarized by the number of patients having any adverse event overall.
| participants | 8-week Washout + Fingolimod (FTY720) | 12-week Washout + Fingolimod (FTY720) | 16-week Washout + Fingolimod (FTY720) |
|---|---|---|---|
| Any Adverse Events | 13 | 12 | 25 |
| Serious Adverse Events | 0 | 0 | 1 |
| Death | 0 | 0 | 0 |
Adverse events were summarized by the number of patients having any adverse event overall.
| participants | 8-week Washout + Fingolimod (FTY720) | 12-week Washout + Fingolimod (FTY720) | 16-week Washout + Fingolimod (FTY720) |
|---|---|---|---|
| Any Adverse Events | 35 | 20 | 28 |
| Serious Adverse Events | 2 | 5 | 3 |
| Death | 0 | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 8-week Washout + Fingolimod (FTY720) | — | 2/50 (4%) | 17/50 (34%) |
| 12-week Washout + Fingolimod (FTY720) | — | 5/42 (11.9%) | 7/42 (16.7%) |
| 16-week Washout + Fingolimod (FTY720) | — | 4/50 (8%) | 14/50 (28%) |
| Event | 8-week Washout + Fingolimod (FTY720) | 12-week Washout + Fingolimod (FTY720) | 16-week Washout + Fingolimod (FTY720) |
|---|---|---|---|
| Multiple sclerosis relapseNervous system disorders | 0/50 | 0/42 | 2/50 |
| Cholecystitis acuteHepatobiliary disorders | 0/50 | 1/42 | 0/50 |
| CholelithiasisHepatobiliary disorders | 0/50 | 1/42 | 0/50 |
| PharyngitisInfections and infestations | 0/50 | 1/42 | 0/50 |
| Heart rate decreasedInvestigations | 0/50 | 1/42 | 0/50 |
| EpilepsyNervous system disorders | 0/50 | 1/42 | 0/50 |
| SyncopeNervous system disorders | 0/50 | 1/42 | 0/50 |
| Depression suicidalPsychiatric disorders | 0/50 | 1/42 | 0/50 |
| BradycardiaCardiac disorders | 0/50 | 0/42 | 1/50 |
| PneumoniaInfections and infestations | 1/50 | 0/42 | 0/50 |
| Event | 8-week Washout + Fingolimod (FTY720) | 12-week Washout + Fingolimod (FTY720) | 16-week Washout + Fingolimod (FTY720) |
|---|---|---|---|
| HeadacheNervous system disorders | 5/50 | 3/42 | 10/50 |
| NasopharyngitisInfections and infestations | 7/50 | 1/42 | 2/50 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 4/50 | 0/42 | 0/50 |
| Oral herpesInfections and infestations | 1/50 | 3/42 | 1/50 |
| SinusitisInfections and infestations | 2/50 | 1/42 | 3/50 |
| Urinary tract infectionInfections and infestations | 3/50 | 1/42 | 0/50 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/50 | 0/42 | 0/50 |
| DizzinessNervous system disorders | 3/50 | 1/42 | 3/50 |
| DepressionPsychiatric disorders | 1/50 | 1/42 | 3/50 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/50 | 0/42 | 1/50 |
Randomized set includes all subjects who receive a randomization number, regardless of whether or not they receive study medication.
| Age, Continuous(Years) | 8-week Washout + Fingolimod (FTY720) | 12-week Washout + Fingolimod (FTY720) | 16-week Washout + Fingolimod (FTY720) | Total |
|---|---|---|---|---|
| Mean | 41.2 ± 10.102 | 41.9 ± 7.445 | 41.8 ± 8.552 | 41.6 ± 8.780 |
| Sex: Female, Male(Participants) | 8-week Washout + Fingolimod (FTY720) | 12-week Washout + Fingolimod (FTY720) | 16-week Washout + Fingolimod (FTY720) | Total |
|---|---|---|---|---|
| Female | 39 | 21 | 32 | 92 |
| Male | 11 | 21 | 18 | 50 |
The record gives a start of Sep 2011, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod
Multiple Sclerosis, Relapsing-Remitting →